Analyzing SELLAS Life Sciences Group (NASDAQ:SLS) and Exelixis (NASDAQ:EXEL)

SELLAS Life Sciences Group (NASDAQ:SLS) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.

Valuation and Earnings

This table compares SELLAS Life Sciences Group and Exelixis”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86 million	($0.23)	-35.61
Exelixis	$2.32 billion	5.59	$782.57 million	$3.01	17.14

Exelixis has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SELLAS Life Sciences Group and Exelixis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Exelixis	35.08%	39.89%	30.23%

Insider and Institutional Ownership

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

SELLAS Life Sciences Group has a beta of 2.5, indicating that its share price is 150% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for SELLAS Life Sciences Group and Exelixis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1	0	1	0	2.00
Exelixis	2	11	9	1	2.39

SELLAS Life Sciences Group currently has a consensus price target of $10.00, indicating a potential upside of 22.10%. Exelixis has a consensus price target of $47.35, indicating a potential downside of 8.23%. Given SELLAS Life Sciences Group’s higher probable upside, analysts plainly believe SELLAS Life Sciences Group is more favorable than Exelixis.

Summary

Exelixis beats SELLAS Life Sciences Group on 12 of the 14 factors compared between the two stocks.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.